Thyme

Metadata

Approved Indications

German Commission E

• Bronchitis
• Symptomatic relief of whooping cough (pertussis)
• Catarrh of the upper respiratory tract

ESCOP

• Internal: Catarrh of the upper airways, bronchitis, supportive use for whooping cough
• Local: Mouthwash for inflammation of the oral mucosa and halitosis

EMA/HMPC

• Traditional use: Cough associated with the common cold
• Well-established use: Covered under combination monographs (thyme + primrose, thyme + ivy)

Agreement/Disagreement Between Bodies

Strong agreement across all three bodies. Commission E and ESCOP are essentially identical in their respiratory indications. The EMA monograph is somewhat more conservative, primarily classifying single-herb thyme as “traditional use” while the combination products receive stronger endorsement.

Conditions Treated

• Acute bronchitis (primary, especially in combination)
• Productive cough
• Catarrh of the upper respiratory tract
• Whooping cough (supportive/symptomatic)
• Oral mucositis (topical, mouthwash)

Mechanism of Action

1. Spasmolytic/Antispasmodic: Thymol and carvacrol (the dominant phenolic monoterpenes) relax bronchial smooth muscle, reducing cough reflex sensitivity and bronchospasm

2. Expectorant: Stimulates ciliary beat frequency and mucus transport in the respiratory epithelium (secretomotoric effect)

3. Antimicrobial: Thymol and carvacrol demonstrate broad-spectrum antibacterial and antifungal activity in vitro. Active against common respiratory pathogens

4. Anti-inflammatory: Reduction of inflammatory mediators in respiratory mucosa

5. Antioxidant: Phenolic compounds (rosmarinic acid, thymol, carvacrol) provide antioxidant protection

Key active constituents:

• Thymol (major) and carvacrol (variable)
• Rosmarinic acid
• Flavonoids (luteolin, apigenin)
• Tannins

Clinical Evidence Summary

Key Clinical Trials

Kemmerich et al. (2006) — Thyme-Primrose vs. Placebo (Pivotal Trial)

• Design: Double-blind, placebo-controlled, multicenter Phase IV study
• Population: 361 outpatients with acute bronchitis and productive cough
• Intervention: Dry extracts of thyme herb + primrose root (Bronchipret TP) vs. placebo
• Primary outcome: Time to 50% reduction in coughing fits from baseline
• Result: Thyme-primrose group reached 50% reduction approximately 2 days earlier than placebo group
• Statistical significance: p < 0.0001
• [Source: Kemmerich et al., Arzneimittelforschung 2006; 56(9):652-660]

Pediatric Open Study (Thyme Syrup)

• Design: Open, multicenter study
• Population: 154 children aged 2 months to 14 years with bronchial catarrh or bronchitis
• Intervention: 15-30 mL daily of thyme syrup (97.6 mg thyme fluid extract per mL) for 7-14 days
• Result: Improvement in cough intensity reported in 93% of patients
• Limitation: Open-label, no control group

Bronchipret Thyme-Ivy Combination

• Additional formulation combining thyme with ivy leaf extract
• Available as oral solution (Bronchipret Saft/juice)
• Clinical studies support this combination as well [NEEDS-RESEARCH: Specific trial data for thyme-ivy combination]

Evidence Limitations

• Monotherapy RCTs are limited; the strongest evidence is for combination products
• Most monotherapy data comes from open-label or traditional use documentation
• No large placebo-controlled monotherapy RCT identified

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Hypersensitivity to thyme or other Lamiaceae family members
• Commission E reports no contraindications for internal use at approved doses

Drug Interactions

• No known drug interactions (per Commission E and ESCOP)
• Studies on interactions with other medications are not available, but no signals have emerged from decades of use

Side Effects

• Commission E: No side effects known at recommended therapeutic doses
• No adverse effects expected from ingestion of thyme at therapeutic doses
• Thyme essential oil (concentrated) may cause skin irritation; this applies to topical use, not oral herbal preparations

Pregnancy and Lactation

• Conflicting guidance:
  • Some sources state no contraindication during pregnancy or lactation
  • EMA/HMPC: “In the absence of adequate data, use during pregnancy and breast-feeding is not recommended”
  • Thyme essential oil in concentrated form is considered contraindicated in pregnancy (uterotonic potential), but this concern applies to essential oil, not herbal tea or extract at standard doses
• Practical consensus: Standard-dose thyme preparations (tea, syrup) are generally considered acceptable, but concentrated essential oil preparations should be avoided in pregnancy [UNCERTAIN]

Clinical Dosage

Thyme Herb (Monotherapy)

Bronchipret TP (Thyme-Primrose Combination)

• Film-coated tablets for adolescents and adults aged 12+
• Oral drops: Typically 40-50 drops (Bronchicum Tropfen) up to 5 times daily

Duration

• Acute conditions: 7-14 days
• Consult physician if symptoms persist beyond 1 week without improvement

Sources

• German Commission E Monograph: Thymi herba
• ESCOP Monograph: Thymi herba
• EMA/HMPC Assessment Report on Thymus vulgaris L. and Thymus zygis L., herba (2013)
• Kemmerich et al. (2006). Arzneimittelforschung, 56(9):652-660.
• Altmeyers Encyclopedia: Thyme herba entry.
• Southern Cross University: Thymus vulgaris monograph.
• Bionorica: Bronchipret product information.

Connections

• Key combination partner with Primrose Cowslip (Bronchipret TP)
• Key combination partner with Ivy Leaf (Bronchipret Thyme-Ivy)
• Compare with Eucalyptus for monoterpene-based respiratory therapy